Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.36 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.36 |
| ▸ | TUBB | P07437 | 3/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498936 | 0.90 | SCN9A (0.45) | SCN9AGRM5NOTUMCTSAMGLL | |
| SCHEMBL2500256 | 0.89 | SCN9A (0.42) | SCN9AGRM5NOTUMMGLLTUBB4A | |
| SCHEMBL2503546 | 0.89 | CTSA (0.39) | SCN9AGRM5NOTUMCTSAMLLT3 | |
| SCHEMBL2503558 | 0.86 | SCN9A (0.49) | SCN9AGRM5NOTUMCTSAMGLL | |
| SCHEMBL1878128 | 0.86 | SCN9A (0.49) | SCN9AGRM5NOTUMEGLN1KMT2A | |
| SCHEMBL2501415 | 0.85 | SCN9A (0.46) | SCN9AGRM5NOTUMCTSAMGLL | |
| SCHEMBL2501417 | 0.84 | BACE1 (0.37) | MLLT3MLLT1 | |
| SCHEMBL2503497 | 0.84 | MGLL (0.49) | SCN9AGRM5NOTUMCTSAMGLL | |
| SCHEMBL2501484 | 0.84 | SCN9A (0.47) | SCN9AGRM5NOTUMCTSAMGLL | |
| SCHEMBL2502816 | 0.84 | GRM5 (0.46) | SCN9AGRM5CTSATUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | claimed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | claimed |
| EP-1937649-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2008-07-02 | — | — | EP | claimed |
| WO-2007042546-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | claimed |
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | GABBR1, GABRB2, GABRB3 | SCN9A 1508/4885GRM5 46/4885NOTUM 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.